Oue T, Fukuzawa M, Kamata S, Okada A
Department of Pediatric Surgery, Osaka University Medical School, Japan.
J Pediatr Surg. 1995 Apr;30(4):528-32. doi: 10.1016/0022-3468(95)90123-x.
Proliferative cell nuclear antigen (PCNA) is a cell-cycle-related nuclear protein that is maximally elevated in late G1 and S phase of proliferating cells. In this study, PCNA was identified immunohistochemically using paraffin section in 67 human neuroblastomas. Percentage of the PCNA-positive nuclei (PCNA index: PCI) ranged from 0% to 75%. There were significant relations between the PCNA expression and mitotic karyorrhexis index (MKI), histological classification, cell concentration, tumor weight, clinical stage, local invasion, lymph node metastasis, liver metastasis, or DNA ploidy. PCI was significantly low in patients who received aggressive chemotherapy before surgery. Patients with PCI higher than 30% showed a worse survival rate compared with those with PCI lower than 10% (P < .01). High PCI significantly related with poor survival, so that PCI may be an independent prognostic factor in neuroblastoma. Although further studies are required, PCNA immunostaining may be useful for assessing proliferating activity and for providing prognostic information in human neuroblastoma.
增殖细胞核抗原（PCNA）是一种与细胞周期相关的核蛋白，在增殖细胞的G1晚期和S期含量最高。在本研究中，采用石蜡切片免疫组织化学法对67例人类神经母细胞瘤中的PCNA进行鉴定。PCNA阳性细胞核的百分比（PCNA指数：PCI）在0%至75%之间。PCNA表达与有丝分裂核溶解指数（MKI）、组织学分类、细胞浓度、肿瘤重量、临床分期、局部浸润、淋巴结转移、肝转移或DNA倍体之间存在显著相关性。术前接受积极化疗的患者PCI显著降低。PCI高于30%的患者与PCI低于10%的患者相比，生存率更差（P <.01）。高PCI与不良生存显著相关，因此PCI可能是神经母细胞瘤的一个独立预后因素。尽管还需要进一步研究，但PCNA免疫染色可能有助于评估人类神经母细胞瘤的增殖活性并提供预后信息。
